CRISPR Therapeutics AG (21)

Browse by Contract Category

Contracts

Letter Agreement dated April 29, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc (Filed With SEC on July 29, 2021)
Second Amendment to Lease dated April __, 2021, by and between CRISPR Therapeutics, Inc. and 33 NYA OWNER (DE) LLC, as successor in interest to CRP/KING 33 NY AVE. OWNER, L.L.C (Filed With SEC on July 29, 2021)
First Amendment to the Strategic Collaboration and License Agreement dated March 17, 2021, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (Filed With SEC on April 27, 2021)
Underwriting Agreement, dated as of June 30, 2020, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC, as representatives of the... (Filed With SEC on July 2, 2020)
Retirement Agreement, dated December 13, 2019, among Casebia Therapeutics Limited Liability Partnership, Bayer HealthCare LLC, CRISPR Therapeutics AG and CRISPR Therapeutics, Inc (Filed With SEC on February 12, 2020)
Joint Venture Termination Agreement, dated December 13, 2019, among Bayer Healthcare LLC (and certain affiliates of Bayer Healthcare LLC for purposes of Article II), CRISPR... (Filed With SEC on February 12, 2020)
First Amendment to Lease dated December 2, 2020, by and between CRISPR Therapeutics, Inc. and CRP/KING 33 NY AVE. OWNER, L.L.C (Filed With SEC on April 27, 2021)
Lease, dated May 5, 2020, by and between CRISPR Therapeutics, Inc. and CRP/KING 33 NY AVE. OWNER, L.L.C (Filed With SEC on April 27, 2021)
Description of Capital Shares (Filed With SEC on February 16, 2021)
Lease, dated July 24, 2020, by and between the Registrant and 105 W First Street Owner, L.L.C (Filed With SEC on July 27, 2020)
Assignment of Sublease and Sub-Sublease, dated December 13, 2019, between Casebia Therapeutics LLC and CRISPR Therapeutics, Inc (Filed With SEC on February 12, 2020)
Option Agreement, dated December 13, 2019, between CRISPR Therapeutics AG and Bayer HealthCare LLC (Filed With SEC on February 12, 2020)
Amendment No. 2 to Research Collaboration Agreement by and between CRISPR Therapeutics AG and ViaCyte, Inc., dated as of October 21, 2019 (Filed With SEC on February 12, 2020)
Amendment No. 1 to Research Collaboration Agreement by and between CRISPR Therapeutics AG and ViaCyte, Inc., dated as of April 30, 2019 (Filed With SEC on February 12, 2020)
Description of Capital Shares (Filed With SEC on February 12, 2020)
Termination Agreement, dated December 27, 2019, by and between CRISPR Therapeutics AG and Rodger Novak (Filed With SEC on December 27, 2019)
Mandate Agreement, dated December 27, 2019, by and between CRISPR Therapeutics AG and Oriolus Consulting LLC (Filed With SEC on December 27, 2019)
Underwriting Agreement, dated as of November 20, 2019, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC, as representatives of the... (Filed With SEC on November 22, 2019)
Open Market Sale AgreementSM, dated August 30, 2019, by and between CRISPR Therapeutics AG and Jefferies LLC (Filed With SEC on August 30, 2019)
Strategic Collaboration and License Agreement dated June 6, 2019, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (Filed With SEC on July 29, 2019)
Amendment No. 2 to the Strategic Collaboration, Option and License Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals... (Filed With SEC on July 29, 2019)